Evofem Biosciences is dedicated to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. Evofem is leveraging its proprietary vaginal pH modulator to develop potential new indications and products for multiple indications, including recurrent bacterial vaginosis, and an early stage MPT product candidate targeting HIV prevention.
EVO200 for the prevention of recurrent Bacterial Vaginosis (BV)
EVO200 is an investigational vaginal pH modulator in development for the prevention of recurrent Bacterial Vaginosis (BV). In a Phase 1 dose-finding trial for this indication, the highest dose formulation of the study drug demonstrated reduced vaginal pH for up to seven days following a single administration.
EVO200 has been designated a QIDP by the FDA for this indication.
MPT Product Candidate
We are collaborating with Orion Biotechnology to evaluate the compatibility and stability of Orion’s novel CCR5 antagonist, OB-002, in Phexxi with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of human immunodeficiency virus (HIV) in women. This collaboration will focus on determining compatibility and stability of OB-002 in Phexxi. Assuming positive results of this initial preclinical work, Evofem and Orion will seek government and philanthropic funding for subsequent clinical trials of the MPT product candidate.
These products have not been approved for marketing by the U.S. Food and Drug Administration or any other regulatory agency.